Predictors of Antiproliferative Effect of Lanreotide Autogel (LA) as First-Line Therapy for Advanced Neuroendocrine Tumors (NETs) Abstract #2027

Introduction: The antiproliferative properties of LA in GEP NETs were demonstrated in the recently published CLARINET study
Aim(s): However, there is relatively limited literature regarding factors that affect progression-free survival(PFS) in NET patients receiving this treatment and we aimed to investigate this further
Materials and methods: Retrospective analysis of 245 treatment-naïve patients with advanced NETs treated with LA(as monotherapy) in our centre. PFS was calculated for the entire cohort. Demographic, clinical and biochemical data were collected. Univariate(UVA) and multivariate(MVA) analyses were performed to determine factors affecting PFS
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Faidon Laskaratos

To read results and conclusion, please login ...

Further abstracts you may be interested in

#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
#1606 Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis
Introduction: The slow-growing character of neuroendocrine tumors (NET) makes it difficult to assess treatment impact on tumor growth.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Frank van Fraeyenhove
#1939 Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors
Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PD Dr. Patricia Grabowski
#2055 Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)
Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Faidon Laskaratos
Authors: Laskaratos F, Shah R, Banks J, Smith J, ...